Skip to main content
Truhout big pharma

Before COVID-19, Big Pharma Was Neglecting Vaccine and Antiviral Research

Drug companies have historically pleased investors by promoting vaccine development programs during disease outbreaks, then quietly dropping them later, according to Dana Brown, director of The Next System Project, a research and development lab for political-economic alternatives. Despite an outbreak raging in the Republic of Congo, the British drug maker GlaxoSmithKline recently gave up its effort to develop a vaccine for Ebola and handed off its research to a nonprofit lab. Ebola is deadly but relatively rare globally, and the market was too small to generate significant profits. In 2017, the massive French drug maker Sanofi pulled out of a partnership with the U.S. Army to develop a vaccine for the mosquito-borne Zika virus.

Read the entire article at Truthout.

Publication date: 2020-04-23
Parent publication: Truthout
Publication URL: https://truthout.org/articles/before-covid-19-big-pharma-was-neglecting-vaccine-and-antiviral-research/

More related work

Default Image

The Democracy Collaborative and The Democracy Collaborative Workers' Union agree to fair severance package for laid-off staff

TDC and union members have agreed to a package of protections that goes well beyond the baseline severance provisions for layoffs agreed to in TDC’s union contract.

read more
Default Image

HAN Anchoring Resilience: Aligning supply chains and impact purchasing for community health summit

The Healthcare Anchor Network (HAN) convened the “Anchoring Resilience: Aligning Supply Chains and Impact Purchasing for Community Health” summit to spark collaboration in the healthcare sector around onshoring and localizing production of PPE and other supplies, with an emphasis on equity, sustainability, and supply chain resilience.

read more
Default Image

Reimagining Personal Protective Equipment (PPE) Supply Chains

The Democracy Collaborative prepared a report, created for the Healthcare Anchor Network, which details the current status of the supply chain of PPE, the market shifts caused by COVID-19, and the potential solutions to ensure capacity within US health systems for the future.

read more